Disruption of the transforming growth factor- (TGF-) pathway is observed in the majority of cancers. To further understand TGF- pathway inactivation in cancer, we stably expressed the v-ErbA oncoprotein in TGF- responsive cells. v-ErbA participates in erythroleukemic transformation of cells induced by the avian erythroblastosis virus (AEV).Here we demonstrate that expression of v-ErbA was sufficient to antagonize TGF--induced cell growth inhibition and that dysregulation of TGF- signaling required that v-ErbA associate with the Smad4 which sequesters Smad4 in the cytoplasm. We also show that AEV-transformed erythroleukemia cells were resistant to TGF--induced growth inhibition and that TGF- sensitivity could be recovered by reducing v-ErbA expression. Our results reveal a novel mechanism for oncogenic disruption of TGF- signaling and provide a mechanistic explanation of v-ErbA activity in AEV-induced erythroleukemia.
INTRODUCTIONThe transforming growth factor- (TGF-) signaling pathway is a major signaling network that controls cell proliferation, differentiation, and tumor suppression (Massague et al., 2000;Attisano and Wrana, 2002;Wakefield and Roberts, 2002). The TGF- cytokine signals through hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors, TGF- type I (TRI) and type II (TRII) receptors (Heldin et al., 1997;Massague et al., 2000). On ligand binding to the TRII receptor, TRII phosphorylates TRI and activates the TßRI kinase (Wrana et al., 1992;Chen and Weinberg, 1995). The signal is further propagated by phosphorylation of the downstream signal transducers Smad2 and Smad3 by the type I receptor kinase (Heldin et al., 1997). Phosphorylated Smad2 and Smad3 form a complex with Smad4 and translocate into the nucleus (Massague et al., 2000). These Smad complexes then interact with other transcription factors and bind the promoter regions of TGF--responsive genes to regulate gene expression (Massague et al., 2000).Insensitivity to antigrowth signals such as TGF- is common in cancer cells (Hanahan and Weinberg, 2000;Massague et al., 2000). Multiple genetic mutations are observed in TGF--insensitive tumor cells, and mechanisms have been identified that explain the disruption of TGF-'s cytostatic activity. These mechanisms include the down-regulation of TGF- receptors, mutations in TGF- signaling components such as Smad4, and mutations in other downstream targets (Hanahan and Weinberg, 2000;Massague et al., 2000). Overexpression of oncoproteins is also implicated in the disruption of TGF- signaling. Tumor cells insensitive to TGF- are known to overexpress diverse oncoproteins such as Cdk4, Ski, Evi-1, Ras, Mdm2, E6/E7, E1A, and PLZF-RAR␣ (Pietenpol et al., 1990;Ewen et al., 1993;Datto et al., 1997;Kurokawa et al., 1998;Sun et al., 1998;Hanahan and Weinberg, 2000;Massague et al., 2000;La et al., 2003;Luo, 2004). Overexpression of HPV-16 E7 and E1A, for example, is shown to cause TGF- resistance in skin keratinocytes by preventing TGF--induced down-regulatio...